Intellectual Property as a Catalyst for Long-Term Value in Psoriasis Biotech Innovation

The biotechnology sector's pursuit of transformative therapies for chronic conditions like psoriasis has become a battleground for intellectual property (IP) dominance. In specialty pharma, where high-margin biologics and innovative delivery mechanisms define competitive advantage, IP strategies are not merely legal safeguards-they are engines of long-term value creation. The psoriasis treatment landscape in 2025 exemplifies this dynamic, with companies leveraging patents, proprietary platforms, and exclusivity extensions to navigate a rapidly evolving market.

The IP-Driven Biologics Arms Race

Janssen Biotech's Stelara (ustekinumab) underscores the strategic importance of layered IP portfolios. While its core composition-of-matter patent expired in 2023, Janssen extended market exclusivity through secondary patents covering formulation improvements and pediatric indications, with protections extending into the 2030s, according to a Pharmacy Times guide. This approach allowed the company to negotiate biosimilar entry terms strategically, as seen in its 2025 settlement with Biocon Biologics and Celltrion, enabling controlled competition while preserving revenue streams, according to a Pharmaphorum report. Similarly, AbbVie's acquisition of Nimble Therapeutics for $200 million in 2024 highlights the value of proprietary platforms. By integrating Nimble's peptide discovery technology, AbbVie secured a preclinical-stage IL-23 inhibitor, reinforcing its pipeline against patent cliffs and expanding its IP moat (as reported by Pharmaphorum).

Novartis, meanwhile, has redefined disease-modifying potential with Cosentyx (secukinumab), an IL-17A inhibitor. The company's biotherapeutics platform enabled rapid development of this drug, which now faces clinical trials exploring its ability to induce long-term remission-a breakthrough that could redefine IP value by shifting treatment paradigms from chronic management to curative interventions, per a Novartis press release.

Biosimilars and the Patent Cliff Dilemma

The rise of biosimilars has intensified IP-related challenges. AbbVie's Skyrizi (risankizumab) and Novartis's Cosentyx face encroachment from lower-cost alternatives, yet both firms have countered by extending exclusivity through real-world evidence studies and patient-centric initiatives. For instance, Novartis's 2025 Direct-to-Patient (DTP) platform for Cosentyx offers a 55% discount for cash-paying patients, mitigating biosimilar competition while maintaining brand loyalty, as noted in the Pharmacy Times guide. This illustrates how IP strategies are increasingly intertwined with pricing and access models, creating hybrid value propositions.

Janssen's experience with Stelara biosimilars (YESINTEK, STEQEYMA) further highlights the dual-edged nature of IP. While patent expirations open markets to competition, they also force innovation in next-generation therapies. Janssen's investment in TREMFYA (guselkumab)-an IL-23 inhibitor with pediatric approvals in 2025-demonstrates how companies pivot to newer targets to sustain IP-driven growth, as reported by Pharmaphorum.

Emerging Therapies and the Future of IP Strategy

Oral small molecules and nanobody-based therapies are reshaping IP dynamics. Icotrokinra, Janssen's IL-23 receptor inhibitor, achieved 65% IGA 0/1 clearance in Phase 3 trials, positioning it as a potential blockbuster with IP protections extending into the late 2030s (per the Novartis press release). Similarly, sonelokimab-a nanobody targeting IL-17F/A-showed 76% PASI 90 responses in Phase 2B trials, with its novel mechanism offering robust patentability despite limited Phase 3 data, as discussed in a NextSteps review. These innovations reflect a shift toward "first-in-class" IP, where differentiation through mechanism of action becomes a primary value driver.

The "knockout therapy" approach-aggressive IL-23 inhibition to eliminate Th17 cells-also introduces new IP opportunities. Risankizumab's 61% sustained PASI 90 response at Week 52 in the KNOCKOUT trial suggests long-term remission potential, which could justify extended exclusivity through orphan drug designations or breakthrough therapy designations, as noted in the NextSteps review.

Strategic Implications for Investors

For investors, the psoriasis treatment market reveals a critical insight: IP is no longer a static asset but a dynamic lever for value creation. Companies that combine robust patent filings with agile clinical development-such as AbbVie's extended-release upadacitinib formulations or Novartis's disease-modifying claims for Cosentyx-are best positioned to weather patent cliffs and biosimilar pressures (as discussed in the Pharmacy Times guide and the Novartis press release). Startups like Alumis Inc. and Nimbus Therapeutics further illustrate this trend, with niche IP strategies targeting oral small molecules and microbiome-based therapies, compiled in a Medical Startups list.

Conclusion

The psoriasis biotech sector in 2025 is a microcosm of the broader specialty pharma landscape: innovation is inextricably linked to IP strategy. As companies navigate patent expirations, biosimilar competition, and the rise of oral therapies, those that treat IP as a catalyst-rather than a cost center-will dominate. For investors, the lesson is clear: prioritize firms that not only secure patents but architect them into ecosystems of clinical, commercial, and strategic advantage.